Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Operating Leases (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Operating Leases for 6 consecutive years, with $56.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases rose 0.88% to $56.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $56.3 million, a 0.88% increase, with the full-year FY2024 number at $60.7 million, up 2.7% from a year prior.
  • Operating Leases was $56.3 million for Q3 2025 at TScan Therapeutics, down from $58.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $60.7 million in Q4 2024 to a low of $3.0 million in Q3 2022.
  • A 5-year average of $39.0 million and a median of $53.4 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 36.74% in 2022, then skyrocketed 1637.45% in 2023.
  • TScan Therapeutics' Operating Leases stood at $4.4 million in 2021, then surged by 1107.04% to $53.0 million in 2022, then increased by 11.56% to $59.1 million in 2023, then rose by 2.7% to $60.7 million in 2024, then fell by 7.3% to $56.3 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Operating Leases are $56.3 million (Q3 2025), $58.1 million (Q2 2025), and $59.9 million (Q1 2025).